Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLARITY 2.0: Repagermanium and Candesartan for COVID-19
NCT05122182Phase 2Terminated
- Sponsor
- University of Sydney
- Start
- Jan 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of repagermanium in coronavirus disease 2019 (COVID-19), sponsored by University of Sydney. Started Jan 2022; status: terminated.
02
Drugs
repagermanium
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05122182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05122182.